1. Meeting Mission & Strategic Objectives
The meeting established an evidence-based framework to address pressing diagnostic delays, streamline clinical referral pathways between primary care and specialized oncology centers, and foster collaborative research across the Kingdom.
Primary Objectives:
- Establish a unified multidisciplinary working group dedicated specifically to GU malignancies in Saudi Arabia.
- Promote seamless clinical synergy between urologic surgeons, uro-oncologists, and medical oncologists.
- Develop standardized, evidence-based referral criteria and diagnostic checklists to eliminate diagnostic bottlenecks.
- Create specialized digital educational platforms to disseminate updated international clinical guidelines.
- Initiate multicenter national research audits to generate local epidemiologic evidence supporting national health policy.
Secondary Objectives:
- Identify systemic root causes of delays in hematuria evaluations and bladder/prostate cancer diagnoses.
- Engage governmental health authorities (MOH, Saudi National Cancer Center) to drive centralized accreditation.
- Address healthcare sector fragmentation between private and public providers.
2. Distinguished Steering Committee & Expert Panel
The inaugural session brought together prominent specialists representing major medical institutions and health clusters across Saudi Arabia:
| Expert Name | Institution & Clinical Title | Country |
|---|---|---|
|
Dr. Ahmed Hashiesh
|
Moderator, Pfizer Medical Affairs | KSA |
|
Dr. Asharf Abosamra
|
Chairman, Saudi Uro-Oncology Group | KSA |
|
Dr. Mohammed Shouki Bazarbashi
|
Consultant Medical Oncologist, King Faisal Specialist Hospital & Research Centre (KFSH&RC), Riyadh | KSA |
|
Dr. Faisal Azam
|
Consultant Medical Oncologist, King Fahd Specialist Hospital, Dammam | KSA |
|
Dr. Bassam Basuliman
|
Consultant Medical Oncologist | KSA |
|
Dr. Mofarej Alhogbani
|
Consultant Urologist, King Fahd Medical City (KFMC), Riyadh | KSA |
|
Dr. Esam Murshid
|
Oncology Department, Ministry of Defense Health Services (MODHS) | KSA |
|
Dr. Sultan Saud Alkhateeb
|
Consultant Urologist, King Faisal Specialist Hospital & Research Centre | KSA |
|
Dr. Faisal Albadaniah
|
Consultant Medical Oncologist, King Abdullah Medical City (KAMC), Makkah | KSA |
3. Patient Journey Challenges & Root Causes
The panel performed an in-depth audit of systemic obstacles across the continuum of patient care in the Kingdom:
1. Significant Diagnostic Delays
2. Fragmented Referral Networks
3. Late-Stage Disease Presentation
4. Misinterpretation of Red Flags
4. Consensus Solutions & Actionable Recommendations
1. National Standardized Referral Pathways & Checklists
Establish mandatory disease-specific checklists for suspected GU cancers. Any adult presenting with painless hematuria must undergo immediate urological referral. Standardized time benchmarks were proposed:
- From symptom recognition to initial specialist consultation: < 2 weeks.
- From biopsy/diagnosis to treatment initiation: < 4 weeks.
2. Dedicated Rapid-Access Hematuria Clinics
Emulating proven international and breast cancer rapid-assessment models, specialized Hematuria Clinics should provide same-day ultrasound, urine cytology, and flexible cystoscopy in major metropolitan centers.
3. Multidisciplinary Tumor Boards (MDT)
Institutional policies must mandate that all non-muscle invasive high-risk and muscle-invasive bladder or metastatic prostate cases be reviewed by a regional multidisciplinary tumor board before major therapeutic commitments.
4. Insights from the Ministry of Defense "Bader Early Detection Program"
Presented by Dr. Esam Murshid, covering a population of 5.8 million beneficiaries. While screening effectively uncovers early lesions, approximately 35% of diagnosed patients encounter internal delays accessing definitive treatment due to authorization bottlenecks, emphasizing that early detection must be coupled with rapid referral logistics.
5. The Saudi GU Working Group Educational Digital Platform
The steering committee formally commissioned the development of an HCP-dedicated digital knowledge hub (saudiguworkinggroup.com):
- Platform Ownership: Solely owned and scientifically moderated by the Saudi GU Working Group Steering Committee to maintain academic integrity.
- Scientific Content: Clinical algorithms, referral checklists, CME webinars, and research registries.
- Logistical Support: Technical facilitation provided by Pfizer without editorial or governance control.
- Access: Streamlined access for verified healthcare providers using QR codes distributed at primary healthcare clinics and academic symposia across the Kingdom.
5. Implementation Roadmap & Action Plan
0 – 3 Months
- Finalize disease-specific referral checklists.
- Complete initial position white paper draft.
- Launch digital educational platform.
- Distribute clinical QR codes to primary clinics.
4 – 9 Months
- Execute multicenter retrospective audit on referral delays.
- Deliver nationwide accredited CME webinars for primary care physicians.
- Present real-world findings to MOH and health cluster executives.
9 – 18 Months
- Pilot specialized Hematuria Clinics in key metropolitan clusters.
- Expand virtual multidisciplinary tumor boards across remote centers.
- Advocate for national accreditation of specialized GU oncology units.
Closing Reflections
The inaugural session reflected exceptional scientific commitment and collaborative determination among Saudi oncology and urology leaders. By aligning medical expertise with national healthcare transformation priorities under Vision 2030, the Saudi GU Working Group establishes a sustainable vehicle to optimize clinical outcomes for cancer patients throughout the Kingdom.